10.24.11
Strengthening its offering in the nutraceutical, pharmaceutical, and personal care markets, Naturex, Avignon, France, will acquire Burgundy Botanical Extracts, a French manufacturer and supplier of plant extracts.
With a total revenue of about €14 million over the last 12 months, Burgundy employs about 60 people at two production sites in France and Spain. The company’s flagship brands and products include grape seed and cranberry extracts, UTIrose, a patented hibiscus extract for use in combating urinary infections and Iridoforce, an extract of harpagophytum used in the prevention of arthrosis and joint diseases.
The acquisition is expected to allow Naturex to strengthen its industrial base and capacities to meet customer needs by developing its expertise in nutraceutical, pharmaceutical and personal care.
"This acquisition fits perfectly with Naturex ‘s strategy for pursuing growth in its different markets. It is an excellent development opportunity in terms of both manufacturing capacity and commercial positioning," said Jacques Dikansky, Naturex ‘s chairman-CEO and founder. "With our successful track record in integrating companies and the promising potential for synergies and cross-selling from this merger, we are confident in our ability to generate sustainable profitable growth, creating value for our customers, employees and investors."
Christophe Magnin, chairman of Burgundy added: "Combining the forces of Burgundy with Naturex will contribute to developing the industrial and scientific strengths of both these two entities. Naturex’s proactive commercial network will promote greater customer proximity and enhance service quality."
With a total revenue of about €14 million over the last 12 months, Burgundy employs about 60 people at two production sites in France and Spain. The company’s flagship brands and products include grape seed and cranberry extracts, UTIrose, a patented hibiscus extract for use in combating urinary infections and Iridoforce, an extract of harpagophytum used in the prevention of arthrosis and joint diseases.
The acquisition is expected to allow Naturex to strengthen its industrial base and capacities to meet customer needs by developing its expertise in nutraceutical, pharmaceutical and personal care.
"This acquisition fits perfectly with Naturex ‘s strategy for pursuing growth in its different markets. It is an excellent development opportunity in terms of both manufacturing capacity and commercial positioning," said Jacques Dikansky, Naturex ‘s chairman-CEO and founder. "With our successful track record in integrating companies and the promising potential for synergies and cross-selling from this merger, we are confident in our ability to generate sustainable profitable growth, creating value for our customers, employees and investors."
Christophe Magnin, chairman of Burgundy added: "Combining the forces of Burgundy with Naturex will contribute to developing the industrial and scientific strengths of both these two entities. Naturex’s proactive commercial network will promote greater customer proximity and enhance service quality."
